18F-fluorodeoxyglucose PET and PET/computed tomography for the evaluation of immunoglobulin G4-related disease: a systematic review

Nucl Med Commun. 2022 Jun 1;43(6):638-645. doi: 10.1097/MNM.0000000000001566. Epub 2022 Apr 19.

Abstract

Background: In the last years, 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) has demonstrated its utility for the evaluation of immunoglobulin G4 (IgG4)-related disease (IgG4RD). The studies are, however, really heterogeneous and different. The aim of this review is, therefore, to analyze the diagnostic performance of 18F-FDG PET and PET/CT for the assessment of IgG4RD.

Methods: A wide literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was made to find relevant published articles about the diagnostic performance of 18F-FDG PET or PET/CT for the evaluation of IgG4RD.

Results: The comprehensive computer literature search revealed 779 articles. On reviewing the titles and abstracts, 756 articles were excluded because the reported data were not within the field of interest. Twenty-three studies were included in the review.

Conclusion: Despite some limitations that affect our review, 18F-FDG PET or PET/CT demonstrated the ability to assess IgG4RD both at initial evaluation and after therapy. In general, no correlation between PET/CT parameters and IgG4 serum levels has been reported. A possible role for 18F-FDG PET/CT to drive differential diagnosis with other disease is starting to emerge.

Publication types

  • Systematic Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Immunoglobulin G
  • Immunoglobulin G4-Related Disease* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals

Substances

  • Immunoglobulin G
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18